<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042025</url>
  </required_header>
  <id_info>
    <org_study_id>AVXS-101-LT-002</org_study_id>
    <secondary_id>2019-002611-26</secondary_id>
    <secondary_id>205305</secondary_id>
    <nct_id>NCT04042025</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi</brief_title>
  <official_title>A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AveXis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AveXis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term follow-up safety and efficacy study of participants in clinical trials
      for spinal muscular atrophy (SMA) Type 1, Type 2 or Type 3 who were treated with onasemnogene
      abeparvovec-xioi. Participants will roll over from their respective previous (parent) study
      into this long-term study for continuous monitoring of safety as well as monitoring of
      continued efficacy (developmental milestones) and durability of response to onasemnogene
      abeparvovec-xioi treatment.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2034</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2034</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who reach developmental milestones</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Assessed via the developmental milestone checklist, formed of 10 yes/no questions. The developmental milestones are: head control, sitting with support, sitting without support, sitting without support for 30 seconds, hands-and-knees crawling, pulls to stand, standing with assistance, walking with assistance, standing alone and walking alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The HFMSE was devised for use in children with SMA Type 2 and Type 3, to give objective information on motor ability and clinical progression. The HFMSE is formed of 33 assessments rated from 0 (unable to perform functional task) to 2 (able to perform functional task unassisted). Higher scores indicated higher levels of motor ability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience a clinically significant change from baseline in pulmonary assessment results</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Participants will receive pulmonary assessments by a pulmonologist or appropriate clinician. Respiratory device data will be reviewed for participants receiving non-invasive ventilatory support.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience swallowing dysfunction</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Assessed via the swallowing function questionnaire, formed of 4 yes/ no questions and 1 body weight question.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience a clinically significant change from baseline in physical examination findings</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The physical examination includes review of the following systems: head, ears, eyes, nose and throat, lungs/thorax, cardiovascular, abdomen, musculoskeletal, neurologic, dermatologic, lymphatic, and genitourinary. In addition, visual inspection of the spine, back, shoulders, and hips looking for spinal curvature and asymmetry will be carried out. Joints will be assessed for loss of mobility and contractures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience a clinically significant change from baseline in vital signs measurements</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Vital sign measurements will include blood pressure, respiratory rate, pulse, axillary temperature, and pulse oximetry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in height measurements</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in weight measurements</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Blood samples will be collected for hematology (including complete blood cell count) and chemistry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience a clinically significant change from baseline in cardiac assessments</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Cardiac assessments will include a 12-lead electrocardiogram, transthoracic echocardiogram and 24-hour Holter monitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results</measure>
    <time_frame>Year 6 to Year 15</time_frame>
    <description>The observational phase questionnaire includes 7 yes/no questions. Observation categories include: adverse events, hospitalizations, concomitant medications, ventilatory support and feeding support.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience at least one serious adverse event (SAE)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>An adverse event (AE) is defined as the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered casually related to the product. An SAE is defined as an AE occurring during any study phase that fulfills one or more of the following criteria:
Results in death
Is immediately life-threatening
Requires in-patient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability or incapacity
Results in a congenital abnormality or birth defect
Is an important medical event that may jeopardize the patient/subject or may require medical intervention to prevent one of the outcomes listed above.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience at least one adverse event of special interest (AESI)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>An AESI is defined as an AE occurring during any study phase that fulfills one of the following criteria:
Liver function enzyme elevations 2 × the upper limit of normal
New neoplasms or malignancies
New incidence or exacerbation of a pre-existing neurologic disorder
New incidence or exacerbation of a prior rheumatologic or other autoimmune disorder
New incidence of hematologic disorder.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Spinal Muscular Atrophy Type I</condition>
  <condition>Spinal Muscular Atrophy Type II</condition>
  <condition>Spinal Muscular Atrophy Type III</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Intravenous (IV) Onasemnogene Abeparvovec-xioi</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants received treatment with IV onasemnogene abeparvovec-xioi in an onasemnogene abeparvovec-xioi parent study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Intrathecal (IT) Onasemnogene Abeparvovec-xioi</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants received treatment with IT onasemnogene abeparvovec-xioi in an onasemnogene abeparvovec-xioi parent study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Onasemnogene Abeparvovec-xioi</intervention_name>
    <description>Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.</description>
    <arm_group_label>Cohort 1: Intravenous (IV) Onasemnogene Abeparvovec-xioi</arm_group_label>
    <arm_group_label>Cohort 2: Intrathecal (IT) Onasemnogene Abeparvovec-xioi</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with SMA (with 1, 2 or 3 copies of SMN2) who received onasemnogene
             abeparvovec-xioi gene replacement therapy in an AveXis clinical study

          -  Participant/parent/legal guardian willing and able to complete the informed consent
             process and comply with study procedures and visit schedule

        Exclusion Criteria:

          -  Parent/legal guardian unable or unwilling to participate in the long-term follow-up
             safety study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doug Feltner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AveXis, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Hospital - David M. Rubenstein Child Health Building</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals Helen DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Unviersity School of Medicine in Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center - Harkness Pavilion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Special Children</name>
      <address>
        <city>Strasburg</city>
        <state>Pennsylvania</state>
        <zip>17579</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Health Specialty Center Dallas Campus</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin, Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Référence des Maladies Neuromusculaires</name>
      <address>
        <city>Liège</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Gianninia Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi Di Milano</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Neurologico di Ricerca</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongsangnam-Do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Mancha Centro</name>
      <address>
        <city>Alcázar De San Juan</city>
        <zip>13600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle Upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gene replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Spinal Muscular Atrophies of Childhood</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

